Valuation : Evaxion A/S

Market Cap 26.1M 22.49M 21.3M 19.3M 36.21M 2.49B 36.4M 253M 97.27M 1.27B 98.04M 95.89M 4.01B P/E 2026 *
-78.3x
P/E 2027 * -209x
Enterprise Value 26.1M 22.49M 21.3M 19.3M 36.21M 2.49B 36.4M 253M 97.27M 1.27B 98.04M 95.89M 4.01B EV / Sales 2026 *
-
EV / Sales 2027 * 5.59x
Free-Float
58.26%
Yield 2026 *
-
Yield 2027 * -
1 day+0.97%
1 week+0.32%
Current month+4.33%
1 month+2.29%
3 months-13.30%
6 months-19.12%
Current year-34.38%
1 week 3.05
Extreme 3.05
3.33
1 month 2.83
Extreme 2.83
3.64
Current year 2.77
Extreme 2.77
5.48
1 year 2.77
Extreme 2.77
12.15
3 years 1.2
Extreme 1.2
68.05
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Chief Executive Officer 59 23/11/2025
Corporate Officer/Principal 49 10/08/2008
Director of Finance/CFO 53 31/10/2024
Director TitleAgeSince
Chairman 58 24/11/2020
Director/Board Member 56 31/12/2017
Director/Board Member 68 24/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
16/04/26 Other

Director

2,376 0.0006%
18/03/26 Other

Chief Financial Officer

645,750 0.1549%
18/03/26 OtherCompany 360,406 0.0864%
Change 5-day change 1-year change 3-year change Capi.($)
+0.97%+0.32%+8.68%-91.99% 26.1M
-0.71%-6.35%-4.87%+9.03% 45.48B
+0.21%-2.98%+340.68%+519.93% 43.69B
+1.74%-2.24%+37.28%+21.57% 43.09B
+1.38%-3.28%+3.23%+65.60% 39.4B
-1.44%-5.26%+8.78%+36.85% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+18.07%+110.32% 16.4B
-0.31%-2.78%+10.47%+30.49% 14.24B
+1.93%-3.55%+74.20%+39.37% 13.28B
Average +0.54%-3.18%+55.17%+82.35% 26.48B
Weighted average by Cap. +0.41%-3.67%+73.15%+123.54%

Financials

2026 *2027 *
Net sales - 4.67M 4.02M 3.81M 3.45M 6.48M 446M 6.51M 45.25M 17.4M 227M 17.54M 17.15M 717M
Net income -15.56M -13.41M -12.7M -11.51M -21.59M -1.49B -21.7M -151M -57.98M -756M -58.44M -57.16M -2.39B -11.81M -10.18M -9.64M -8.74M -16.39M -1.13B -16.47M -114M -44.02M -574M -44.36M -43.39M -1.81B
Net Debt - -
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
11/09/26 US$3.130 +0.97% 30,259
10/09/26 US$3.100 -5.78% 87,194
09/09/26 US$3.290 +3.79% 61,376
08/09/26 US$3.170 +1.60% 63,850
04/09/26 US$3.120 +1.30% 38,328
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.130USD
Average target price
11.25USD
Spread / Average Target
+259.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVAX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!